After radical prostatectomy (RP) for clinically localized prostate cancer (CaP) 15-40% of men will show clinical or biochemical evidence of disease progression. Many of these failures are due to occult metastatic disease. This project explores the phenomenology of prostate cancer dissemination through application of reverse transcriptase polymerase chain reaction (RT-PCR).
The specific aims of this project are: 1) To test the hypothesis that extra-prostatic tumor cells are present in most patients with clinically localized CaP yet clear following RP in those patients cured of CaP, but do not clear or later reappear when recurrent disease develops. 2) To examine the phenomenology of RT-PCR results in the bone marrow following prostate seed implantation (PSI) and compare the results with those following RP. 3) To test RT-PCR assays for the CaP markers, hK2 and PSMA in bone marrow specimens and examine the effect of various treatments (RP, radiation, Hormones) on the expression of these markers alone and in combination with PSA. 4) To assess new RT-PCR assays for markers of virulence developed by the technical core. 5) To test new semi-quantitative gene expression assays the hypothesis that as disease severity increases the number of cells expressing genes associated with prostate cancer will increase. Pre-operative and serial post-operative bone marrow aspirates will be collected from patients undergoing radical prostatectomy. Specimens will be analyzed with an RT-PCR assay for PSA expression. Results will be compared with long-term (5 year) disease free survival and biochemical recurrence as defined by a chemiluminescent assays with a biological detection limit of 0.008 ng/ml. A similar study will also be performed on patients undergoing PSI. The banked cDNA from the RP and PSI patients will also be tested by RT-PCR assays described in the Technical Core, which may help assess the metastatic potential of cell detection in the bone marrow, will also be studied. Finally, we will examine with transcription mediated amplification whether semi-quantitative techniques, which will allow us to know the relative expression of PSA, PSMA, and hK2, provide additional information beyond that provided by the current qualitative assays.

Project Start
1999-09-01
Project End
2000-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Nguyen, Holly M; Corey, Eva (2011) Methodology to investigate androgen-sensitive and castration-resistant human prostate cancer xenografts in preclinical setting. Methods Mol Biol 776:295-312
Roudier, Martine P; Morrissey, Colm; True, Lawrence D et al. (2008) Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180:1154-60
Pfitzenmaier, Jesco; Ellis, William J; Arfman, Edward W et al. (2006) Telomerase activity in disseminated prostate cancer cells. BJU Int 97:1309-13
Roudier, M P; True, L D; Vessella, R L et al. (2004) Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity. J Clin Pathol 57:321-3
Roudier, Martine P; Corey, Eva; True, Lawrence D et al. (2004) Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res 118:311-39
Brubaker, K D; Corey, E; Brown, L G et al. (2004) Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91:151-60
Blaszczyk, Natalie; Masri, Bassam A; Mawji, Nasrin R et al. (2004) Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 10:1860-9
Roudier, M P; Vesselle, H; True, L D et al. (2003) Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20:171-80
Meehan, Katie L; Sadar, Marianne D (2003) Androgens and androgen receptor in prostate and ovarian malignancies. Front Biosci 8:d780-800
Corey, Eva; Quinn, Janna E; Buhler, Kent R et al. (2003) LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 55:239-46

Showing the most recent 10 out of 48 publications